Search results

From Self-sufficiency
Jump to: navigation, search

Page title matches

Page text matches

  • ...mia(CLL) through folic acid "depletion" and resultant high levels of folic acid in the mutant lymphocytes that characterize CLL Chloramphenicol is metabolised by the liver to chloramphenicol [[glucuronic acid|glucuronate]] (which is inactive). In liver impairment, the dose of chlora
    29 KB (3,876 words) - 16:42, 27 September 2010
  • ...Pharmaceutical]] in the 1970s as a result of their efforts to overcome the acid instability of erythromycin. ...c Total Synthesis of Erythromycin. 1. Synthesis of an Erythronolide A Seco Acid Derivative via Asymmetric Induction. J. Am. Chem. Soc. 1981. 103. 3210-3213
    19 KB (2,731 words) - 17:52, 18 September 2010
  • ..., early satiety, bloating, substernal burning, egg-smelling halitosis, and acid indigestion may be exacerbated by eating and are generally present in the a {{Nucleic acid inhibitors}}
    19 KB (2,528 words) - 16:43, 27 September 2010
  • ...rately; the reason is because they inhibit successive steps in the [[folic acid|folate]] synthesis pathway (see diagram below). ...inhibitor]]s of the enzyme, inhibiting the production of [[dihydropteroic acid]].
    10 KB (1,346 words) - 16:43, 27 September 2010
  • ...'' synthesis pathway for dTTP]</ref>. Bacteria are unable to take up folic acid from the environment (i.e. the infection host) and are thus dependent on th ...y low level of thrombocytes (cells that help blood clot) by lowering folic acid levels and associated bone marrow blood cell formation.
    8 KB (1,056 words) - 20:12, 10 September 2010
  • ...8(48),9,11,14,16,29(45),30,32,34,36,38,46,49- pentadecaene- 40- carboxylic acid ...8414736 |doi=10.1039/b717538h}}</ref> The [[enzymes]] determine the amino acid sequence during its assembly through its 7 modules. Before Vancomycin is as
    31 KB (4,198 words) - 16:43, 27 September 2010
  • ...ntibacterial]], dapsone inhibits [[bacteria]]l synthesis of [[dihydrofolic acid]], via competition with [[4-Aminobenzoic_acid|para-aminobenzoate]] for the ...oxide is an antagonist of antiinflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase. Biochem Pharmacol 1993; 45:2003-2010.</ref><
    15 KB (2,087 words) - 16:43, 27 September 2010
  • ...sistant ''Staphylococcus aureus'' ([[MRSA]]) in combination with [[fusidic acid]]. It is used in prophylactic therapy against ''Neisseria meningitidis'' ([ ...id17055024">{{cite journal |author=Charity JC, Katz E, Moss B |title=Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold prot
    18 KB (2,471 words) - 16:43, 27 September 2010
  • ...bacilli. It works by obstructing the formation of [[cell wall]]. [[Mycolic acid]]s attach to the 5'-hydroxyl groups of [[D-arabinose]] residues of [[arabin
    3 KB (384 words) - 16:43, 27 September 2010
  • ...ve and is generally well tolerated. It is manufactured from [[isonicotinic acid]], which is produced from [[4-Methylpyridine|4-methylpyridine]].<ref>{{Cite ...[[fatty acid synthase]]. This process inhibits the synthesis of [[mycolic acid]], required for the [[mycobacterium|mycobacterial]] cell wall. A range of r
    12 KB (1,566 words) - 16:43, 27 September 2010
  • ...nthase]] (FAS) I, which is required by the bacterium to synthesise [[fatty acid]]s<!-- ...elch J, Jacobs WR pi. Pyrazinoic acid and its n'Propyl Ester Inhibit Fatty Acid Synthase I in Replicating Tubercle Bacilli. Antimicrob Agents Chemother. 20
    12 KB (1,557 words) - 16:44, 27 September 2010
  • The terminal two amino acid residues of the [[murein]] precursor [[lipid II]] consist of [[D-alanine]],
    5 KB (602 words) - 16:44, 27 September 2010
  • ...1">{{cite journal |author=Quémard A, Lanéelle G, Lacave C |title=Mycolic acid synthesis: a target for ethionamide in mycobacteria? |journal=Antimicrob. A
    2 KB (278 words) - 16:44, 27 September 2010
  • ...Translocation by Kanamycin and Viomycin: A Comparative Study with Fusidic Acid, Biochem.Biophys.Res.Commun. 92, pp.647-654, 1980</ref>.
    4 KB (503 words) - 16:44, 27 September 2010
  • ...[Bioavailability]] is not significantly affected by the absence of stomach acid. Concentrations measured in the urine, tears, and skin are approximately 10
    11 KB (1,533 words) - 16:44, 27 September 2010
  • 21,25,27,29,31-hexaene-36-carboxylic acid
    7 KB (941 words) - 16:44, 27 September 2010
  • ...cyclo [33.3.1] nonatriaconta- 19,21,23,25,27,29,31-heptaene- 36-carboxylic acid
    13 KB (1,785 words) - 16:44, 27 September 2010
  • ...with [[dichloromethane]]. As formed under acidic conditions, [[hydroiodic acid]] (HI) is a stronger reducing agent.<ref>N. N. Greenwood, A. Earnshaw, ''Ch
    23 KB (3,281 words) - 16:44, 27 September 2010
  • is a [[guanosine]] [[nucleic acid analogues|analogue]] [[antiviral drug]], marketed under trade names such as
    14 KB (1,878 words) - 16:44, 27 September 2010
  • |excretion=[[Kidney|Renal]] (1.2% abacavir, 30% 5'-carboxylic acid metabolite, 36% 5'-glucuronide metabolite, 15% unidentified minor metabolit
    8 KB (1,124 words) - 16:44, 27 September 2010

View (previous 20 | next 20) (20 | 50 | 100 | 250 | 500)